|
18 Nov 2021 |
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
|
|
18 Nov 2021 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
|
|
17 Nov 2021 |
AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
|
|
16 Nov 2021 |
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
|
|
16 Nov 2021 |
BioArctic develops new antibody treatment for ALS
|
|
16 Nov 2021 |
Celltrion’s Monoclonal Antibody Treatment regdanvimab, Approved by the European Commission for the Treatment of COVID-19
|
|
16 Nov 2021 |
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
|
|
16 Nov 2021 |
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
|
|
16 Nov 2021 |
OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Data presented at the 36th Annual Society for Immunotherapy of Cancer (SITC) Meeting
|
|
16 Nov 2021 |
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
|
|
14 Nov 2021 |
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
|
|
14 Nov 2021 |
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
14 Nov 2021 |
Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021
|
|
14 Nov 2021 |
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
|
|
14 Nov 2021 |
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
|
|
14 Nov 2021 |
NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting
|
|
14 Nov 2021 |
Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021
|
|
14 Nov 2021 |
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
|
|
14 Nov 2021 |
Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
|
|
14 Nov 2021 |
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
|
|
14 Nov 2021 |
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
|
|
14 Nov 2021 |
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
|
|
14 Nov 2021 |
Innate Pharma Highlights New NK Cell Engager Data With Partner Sanofi at SITC Annual Meeting
|
|
14 Nov 2021 |
Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
14 Nov 2021 |
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
|
